糖尿病患者感染SARS-CoV-2及COVID-19风险的系统综述再评价
该综述由世界卫生组织委托,汇总截至2020年12月3日的112篇系统综述,评估糖尿病患者感染SARS-CoV-2及发生重症COVID-19的风险。证据一致表明糖尿病是COVID-19重症和死亡的危险因素,血糖水平越高预后越差,1型糖尿病结局劣于2型糖尿病,但无适当数据判断糖尿病是否增加感染风险。
要点
- 糖尿病是COVID-19重症和死亡的危险因素,证据一致。
- 糖尿病患者感染前后血糖水平越高,COVID-19结局越差。
- 1型糖尿病患者的COVID-19结局劣于2型糖尿病。
核心结论
- 无数据表明糖尿病易感SARS-CoV-2感染。
- 数据一致显示糖尿病增加COVID-19重症风险。
- 糖尿病与COVID-19不良结局均与社会经济劣势相关,二者交叉需特别关注。
研究设计与样本
- 世界卫生组织委托的系统综述再评价。
- 检索Cochrane COVID-19研究注册库、Embase、MEDLINE和LitCOVID,截至2020年12月3日。
- 纳入112篇系统综述,采用叙述性综合和效应方向图展示。
主要发现
- 糖尿病是COVID-19重症和死亡的危险因素,证据一致。
- ICU入住数据较少,但现有数据也提示风险增加。
- 糖尿病患者感染前和感染期间血糖水平越高,COVID-19结局越差。
- 1型糖尿病结局劣于2型糖尿病。
- 无适当数据判断糖尿病是否增加SARS-CoV-2感染风险。
临床怎么用
- 应重视糖尿病患者COVID-19重症和死亡风险的增加。
- 需关注糖尿病患者感染前后血糖水平对COVID-19结局的影响。
- 1型糖尿病患者可能需更密切的COVID-19风险管理。
局限性
- 多数纳入综述的数据来自回顾性观察性研究。
- 各综述对偏倚风险的评估程度不一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This review was commissioned by the World Health Organization and presents a summary of the latest research evidence on the impact of coronavirus disease 2019 (COVID-19) on people with diabetes (PWD). PURPOSE: To review the evidence regarding the extent to which PWD are at increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and/or of suffering its complications, including associated mortality. DATA SOURCES: We searched the Cochrane COVID-19 Study Register, Embase, MEDLINE, and LitCOVID on 3 December 2020. STUDY SELECTION: Systematic reviews synthesizing data on PWD exposed to SARS-CoV-2 infection, reporting data on confirmed SARS-CoV-2 infection, admission to hospital and/or to intensive care unit (ICU) with COVID-19, and death with COVID-19 were used. DATA EXTRACTION: One reviewer appraised and extracted data; data were checked by a second. DATA SYNTHESIS: Data from 112 systematic reviews were narratively synthesized and displayed using effect direction plots. Reviews provided consistent evidence that diabetes is a risk factor for severe disease and death from COVID-19. Fewer data were available on ICU admission, but where available, these data also signaled increased risk. Within PWD, higher blood glucose levels both prior to and during COVID-19 illness were associated with worse COVID-19 outcomes. Type 1 diabetes was associated with worse outcomes than type 2 diabetes. There were no appropriate data for discerning whether diabetes was a risk factor for acquiring SARS-CoV-2 infection. LIMITATIONS: Due to the nature of the review questions, the majority of data contributing to included reviews come from retrospective observational studies. Reviews varied in the extent to which they assessed risk of bias. CONCLUSIONS: There are no data on whether diabetes predisposes to infection with SARS-CoV-2. Data consistently show that diabetes increases risk of severe COVID-19. As both diabetes and worse COVID-19 outcomes are associated with socioeconomic disadvantage, their intersection warrants particular attention.
引用
- Hartmann-Boyce J, Rees K, Perring JC, et al. Risks of and From SARS-CoV-2 Infection and COVID-19 in People With Diabetes: A Systematic Review of Reviews. Diabetes Care. 2021. PMID: 34711637. doi:10.2337/dc21-0930
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。